Unknown PHASE3 INTERVENTIONAL 2-arm NCT00697021

Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance (TEG)

Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI

Sponsor: Assaf-Harofeh Medical Center

Conditions Acute ST SEgment Elevation Myocardial Infarction

Interventions Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG Aspirin 100mg and Plavix 75mg

Updated 5 times since 2017 Last updated: Jun 12, 2008 Started: Jun 30, 2008 Primary completion: Jun 30, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute ST SEgment Elevation Myocardial Infarction, this trial is ongoing. The trial is conducted by Assaf-Harofeh Medical Center and has accumulated 5 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assaf-Harofeh Medical Center

Data source: Assaf-Harofeh Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zerrifin, Israel